Find therapies in clinical trials near you

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.

A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.

A Study of Tulmimetostat and Luxdegalutamide Compared to Standard Treatment in Men with Advanced Prostate Cancer That No Longer Responds to Hormone Therapy

A Study of Tulmimetostat and Luxdegalutamide Compared to Standard Treatment in Men with Advanced Prostate Cancer That No Longer Responds to Hormone Therapy

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Study on Re-treatment with Lutetium (177Lu) Vipivotide Tetraxetan for Men with Metastatic Castration-Resistant Prostate Cancer

Study on Re-treatment with Lutetium (177Lu) Vipivotide Tetraxetan for Men with Metastatic Castration-Resistant Prostate Cancer

Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Prostate Cancer After Radiation and Hormone Therapy

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Prostate Cancer After Radiation and Hormone Therapy

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Localized or Locally Advanced Prostate Cancer Eligible for Surgery

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Localized or Locally Advanced Prostate Cancer Eligible for Surgery

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Phase 2 study of lutetium (177Lu) vipivotide tetraxetan with ADT and darolutamide in patients with metastatic hormone‑sensitive prostate cancer

Phase 2 study of lutetium (177Lu) vipivotide tetraxetan with ADT and darolutamide in patients with metastatic hormone‑sensitive prostate cancer

Efficacy and safety of lutetium‑177 vipivotide tetraxetan with gozetotide in patients with progressive adenoid cystic carcinoma of the salivary glands

Efficacy and safety of lutetium‑177 vipivotide tetraxetan with gozetotide in patients with progressive adenoid cystic carcinoma of the salivary glands